What sector does Elevance Health belong to?

Elevance Health operates in the Health Care sector, specifically the Managed Health Care industry, and is listed on the US markets.

What is the current share price of ELV?

As of the latest available quote, ELV traded at $418.72. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of ELV?

Elevance Health has a price-to-earnings (P/E) ratio of about 18.52. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of ELV?

The market capitalisation of Elevance Health is approximately $94.04B.

Is Elevance Health profitable?

For its latest reported financial year, Elevance Health recorded a net profit margin of about 2.84%.

Does ELV pay a dividend?

Elevance Health currently has a dividend yield of about 1.65%.

What is the return on equity (ROE) of ELV?

Elevance Health has a return on equity (ROE) of about 12.62%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of ELV?

Over the past 52 weeks, ELV has traded between a low of $274.84 and a high of $436.24.

Elevance Health

ELV US Health Care Managed Health Care

S&P 500

$418.72

+0.52%

Delayed · cached 15 min

Fair value analysis

ELV

Elevance Health

$418.72

Close used for this calculation

$378.05Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

53/100

Profitability11/25

Returns10/25

Balance Sheet16/25

Efficiency16/25

Growth6/25

Good

Quality radar

Consensus fair value

$378.05

Near FV

▼ -9.7% against the close used

Model range $247.81 – $504.20

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear$247.81Fair value$378.05Bull$504.20

FairClose

52-week traded range

52W low $280.7452W high $426.79

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Elevance Health closed at $418.72, 10.8% above the consensus fair value of $378.05 drawn from 9 valuation models.

Financial DNA score 53/100 — Good. P/E of 16.6x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

$280.51

-33.0%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

Graham Number

$342.05

-18.3%

√(22.5 × EPS × BVPS)

EPS=25.21, BVPS=206.27 · outside Graham range (P/E 16.6, P/B 2) — asset-light, treat as a rough floor

P/E Fair Value

$504.20

+20.4%

EPS × 20x (sector P/E)

EPS=25.21, Sector P/E=20x

Peter Lynch (PEG)

$247.81

-40.8%

EPS × Growth% (PEG = 1 is fair)

EPS=25.21, g=9.8%

EV/EBITDA

$480.99

+14.9%

(EBITDA × 14.9x − Net Debt) ÷ Shares

EBITDA=8.75B

Dividend Discount (DDM)

$368.56

-12.0%

D1 ÷ (r − g) where D1 = D0×(1+g)

D0=6.83, r=10%, g=8%

Book Value (P/B)

$341.37

-18.5%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=206.27, ROE=12.6%, g=6%, r=10%

Reverse DCF

$418.72

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 4.6% | Historical: 9.8%

Margin of Safety

$281.69

-32.7%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=375.59, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer